Business Wire

Probiotics for Corals Boost Resilience, Help Prevent Mortality

18.8.2021 10:00:00 EEST | Business Wire | Press release

Share

A new study shows probiotics to be helpful protagonists in boosting coral health and preventing mortality in the face of environmental stressors, such as warming oceans and changing climate conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005016/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

KAUST Marine Scientist Dr. Raquel Peixoto administers probiotics, or Beneficial Microorganisms for Corals (BMC), to Pocillopora verrucosa coral in controlled aquarium environments. (Photo: KAUST)

Published in Science Advances, the study details research conducted by the Federal University of Rio de Janeiro, Brazil, in collaboration with the Red Sea Research Center at King Abdullah University of Science and Technology (KAUST). It is the first of its kind to show that Beneficial Microorganisms for Corals (BMC) can protect bleached corals from death, by stimulating immune processes that help them rebuild their microbiome environment and offset “post-heat stress disorder” symptoms driven by thermal stress.

The scientists created a probiotic using microbes derived from the coral itself, selecting strains with traits deemed likeliest to boost resilience. They isolated, plated and studied hundreds of bacteria strains for their potential to serve as BMCs. They inoculated two groups of corals in controlled environments—those with probiotics and those with a placebo, exposing both to the same degree of thermal stress. Probiotics increased the stability and survivorship in the algae-coral host relationship by more than 40%.

Dr. Raquel Peixoto, lead author and KAUST marine scientist, said, “Whereas all corals initially bleached and showed signs of stress, those with BMCs survived and returned to their original state, with results similar to corals that had not been exposed at all. Corals without BMCs sustained damage or died. The holistic formula equipped the corals with hearty traits for buffering and surviving heat trauma.”

Contributing author Dr. Chris Voolstra, reef genomicist and big data specialist, said, “The study is remarkable for demonstrating ‘genetic reprogramming,’ meaning, microbes prompt the coral to make beneficial changes at the genetic level rather than superimpose their functions onto the host. This is a key understanding about the mechanisms underlying coral probiotics that was not known before.”

The study received funding from the Great Barrier Reef Foundation’s Out of the Blue Box Reef Innovation Challenge, for new ideas to protect coral reefs, and was supported by the Tiffany & Co Foundation.

Great Barrier Reef Foundation Managing Director Anna Marsden said, “Pioneering science such as this provides hope for the future of the Great Barrier Reef and coral reefs globally, which are coming under increasing pressure from climate change.”

Read the full article here.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Najdat Boukarroum
Najdat.boukarroum@kaust.edu.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release

Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye